Limits...
Effects of prednisone on eosinophilic bronchitis in asthma: a systematic review and meta-analysis.

Sakae TM, Maurici R, Trevisol DJ, Pizzichini MM, Pizzichini E - J Bras Pneumol (2014)

Bottom Line: The independent variables were the use, dose, and duration of prednisone treatment.The pooled analysis of the pre- vs. post-treatment data revealed a significant mean reduction in sputum eosinophils (↓8.18%; 95% CI: 7.69-8.67; p < 0.001), sputum IL-5 (↓83.64 pg/mL; 95% CI: 52.45-114.83; p < 0.001), and sputum ECP (↓267.60 µg/L; 95% CI: 244.57-290.63; p < 0.0001), as well as a significant mean increase in post-bronchodilator FEV1 (↑8.09%; 95% CI: 5.35-10.83; p < 0.001).This reduction in the inflammatory response was accompanied by a significant increase in post-bronchodilator FEV1.

View Article: PubMed Central - PubMed

Affiliation: Federal University of Santa Catarina, Florianópolis, Brazil.

ABSTRACT

Objective: To evaluate the effect size of oral corticosteroid treatment on eosinophilic bronchitis in asthma, through systematic review and meta-analysis.

Methods: We systematically reviewed articles in the Medline, Cochrane Controlled Trials Register, EMBASE, and LILACS databases. We selected studies meeting the following criteria: comparing at least two groups or time points (prednisone vs. control, prednisone vs. another drug, or pre- vs. post-treatment with prednisone); and evaluating parameters before and after prednisone use, including values for sputum eosinophils, sputum eosinophil cationic protein (ECP), and sputum IL-5-with or without values for post-bronchodilator FEV1-with corresponding 95% CIs or with sufficient data for calculation. The independent variables were the use, dose, and duration of prednisone treatment. The outcomes evaluated were sputum eosinophils, IL-5, and ECP, as well as post-bronchodilator FEV1.

Results: The pooled analysis of the pre- vs. post-treatment data revealed a significant mean reduction in sputum eosinophils (↓8.18%; 95% CI: 7.69-8.67; p < 0.001), sputum IL-5 (↓83.64 pg/mL; 95% CI: 52.45-114.83; p < 0.001), and sputum ECP (↓267.60 µg/L; 95% CI: 244.57-290.63; p < 0.0001), as well as a significant mean increase in post-bronchodilator FEV1 (↑8.09%; 95% CI: 5.35-10.83; p < 0.001).

Conclusions: In patients with moderate-to-severe eosinophilic bronchitis, treatment with prednisone caused a significant reduction in sputum eosinophil counts, as well as in the sputum levels of IL-5 and ECP. This reduction in the inflammatory response was accompanied by a significant increase in post-bronchodilator FEV1.

Show MeSH

Related in: MedlinePlus

Redução dos níveis de proteína catiônica eosinofílica no escarro apóstratamento com prednisona ou prednisolona por via oral.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263337&req=5

f10: Redução dos níveis de proteína catiônica eosinofílica no escarro apóstratamento com prednisona ou prednisolona por via oral.

Mentions: A análise conjunta (n = 198) revelou uma redução média de seis vezes no número deeosinófilos no escarro após o tratamento (↓8,2%; IC95%: 7,7-8,7; p < 0,001;Figura 2). Dentre os estudos queavaliaram IL-5 (em pg/mL) antes e depois do tratamento com prednisona ouprednisolona (n = 114), houve uma redução média de aproximadamente quatro vezesnos níveis de IL-5 (↓83,6; IC95%: 52,5-83,6; p < 0,001; Figura 3). Além disso, dentre os estudos que avaliaram a PCE(em μg/L) em indivíduos tratados com prednisona ou prednisolona (n = 80), otratamento resultou em uma redução média de cinco vezes nos níveis de PCE (↓267,6;IC95%: 244,6-290,6; p < 0,001; Figura 4).


Effects of prednisone on eosinophilic bronchitis in asthma: a systematic review and meta-analysis.

Sakae TM, Maurici R, Trevisol DJ, Pizzichini MM, Pizzichini E - J Bras Pneumol (2014)

Redução dos níveis de proteína catiônica eosinofílica no escarro apóstratamento com prednisona ou prednisolona por via oral.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263337&req=5

f10: Redução dos níveis de proteína catiônica eosinofílica no escarro apóstratamento com prednisona ou prednisolona por via oral.
Mentions: A análise conjunta (n = 198) revelou uma redução média de seis vezes no número deeosinófilos no escarro após o tratamento (↓8,2%; IC95%: 7,7-8,7; p < 0,001;Figura 2). Dentre os estudos queavaliaram IL-5 (em pg/mL) antes e depois do tratamento com prednisona ouprednisolona (n = 114), houve uma redução média de aproximadamente quatro vezesnos níveis de IL-5 (↓83,6; IC95%: 52,5-83,6; p < 0,001; Figura 3). Além disso, dentre os estudos que avaliaram a PCE(em μg/L) em indivíduos tratados com prednisona ou prednisolona (n = 80), otratamento resultou em uma redução média de cinco vezes nos níveis de PCE (↓267,6;IC95%: 244,6-290,6; p < 0,001; Figura 4).

Bottom Line: The independent variables were the use, dose, and duration of prednisone treatment.The pooled analysis of the pre- vs. post-treatment data revealed a significant mean reduction in sputum eosinophils (↓8.18%; 95% CI: 7.69-8.67; p < 0.001), sputum IL-5 (↓83.64 pg/mL; 95% CI: 52.45-114.83; p < 0.001), and sputum ECP (↓267.60 µg/L; 95% CI: 244.57-290.63; p < 0.0001), as well as a significant mean increase in post-bronchodilator FEV1 (↑8.09%; 95% CI: 5.35-10.83; p < 0.001).This reduction in the inflammatory response was accompanied by a significant increase in post-bronchodilator FEV1.

View Article: PubMed Central - PubMed

Affiliation: Federal University of Santa Catarina, Florianópolis, Brazil.

ABSTRACT

Objective: To evaluate the effect size of oral corticosteroid treatment on eosinophilic bronchitis in asthma, through systematic review and meta-analysis.

Methods: We systematically reviewed articles in the Medline, Cochrane Controlled Trials Register, EMBASE, and LILACS databases. We selected studies meeting the following criteria: comparing at least two groups or time points (prednisone vs. control, prednisone vs. another drug, or pre- vs. post-treatment with prednisone); and evaluating parameters before and after prednisone use, including values for sputum eosinophils, sputum eosinophil cationic protein (ECP), and sputum IL-5-with or without values for post-bronchodilator FEV1-with corresponding 95% CIs or with sufficient data for calculation. The independent variables were the use, dose, and duration of prednisone treatment. The outcomes evaluated were sputum eosinophils, IL-5, and ECP, as well as post-bronchodilator FEV1.

Results: The pooled analysis of the pre- vs. post-treatment data revealed a significant mean reduction in sputum eosinophils (↓8.18%; 95% CI: 7.69-8.67; p < 0.001), sputum IL-5 (↓83.64 pg/mL; 95% CI: 52.45-114.83; p < 0.001), and sputum ECP (↓267.60 µg/L; 95% CI: 244.57-290.63; p < 0.0001), as well as a significant mean increase in post-bronchodilator FEV1 (↑8.09%; 95% CI: 5.35-10.83; p < 0.001).

Conclusions: In patients with moderate-to-severe eosinophilic bronchitis, treatment with prednisone caused a significant reduction in sputum eosinophil counts, as well as in the sputum levels of IL-5 and ECP. This reduction in the inflammatory response was accompanied by a significant increase in post-bronchodilator FEV1.

Show MeSH
Related in: MedlinePlus